Featured News

2023 promises to be a year full of robust research, advocacy, and education efforts on behalf of our patient community.

The Celiac Disease Foundation is pleased to announce it will provide patient recruitment and eligibility screening for Anokion’s phase 1b/2 clinical trial for KAN-101.

Comments submitted to U.S. Preventive Services Task Force on Draft Research Plan: Preventive Services for Food Insecurity.

The Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.

Patients Who Have Participated In a Celiac Disease Clinical Trial Needed for 2021 Patient Education & Advocacy Summit.

The first mice with characteristics of celiac disease have been developed at the University of Chicago Celiac Disease Center. For the first time researchers can observe celiac disease onset as the mouse’s immune system launches a coordinated attack against gluten.

On April 9, 2019, Marilyn G. Geller, CEO of the Celiac Disease Foundation, testified before the House Appropriations Subcommittee overseeing the funding for the Department of Health and Human Services, including the National Institutes of Health (NIH).

In this one-on-one interview with Gluten-Free Living Editorial Director Maureen McCarthy, CEO Marilyn Geller discusses the Foundation’s history, research and outreach goals, and the importance of partnering with GFL.